Trial Profile
A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-066
- Sponsors Bristol-Myers Squibb
- 13 Sep 2022 Results of pooled-analysis of immune checkpoint inhibitor (ICI) trials (CheckMate [CM] 066, 067, 069 & 511) presented at the 47th European Society for Medical Oncology Congress
- 01 Nov 2021 Results published in the Value in Health
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.